erlotinib hydrochloride has been researched along with snx 2112 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (snx 2112) | Trials (snx 2112) | Recent Studies (post-2010) (snx 2112) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 58 | 1 | 49 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | snx 2112 (IC50) |
|---|---|---|---|
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | 0.002 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 1.2645 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 1.1262 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.531 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 0.7585 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barabasz, A; Fadden, P; Foley, B; Hall, S; Huang, K; Rice, JW; Scott, A; Steed, P; Veal, JM | 1 |
1 other study(ies) available for erlotinib hydrochloride and snx 2112
| Article | Year |
|---|---|
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |